Kailera Therapeutics fast-tracked its entry into the obesity drug market by licensing four clinical-stage therapies from China’s Hengrui, reflecting a broader shift as U.S. firms tap China’s growing pharmaceutical innovation. With $400 million in backing and a leadership team built for speed, Kailera aims to outpace competitors by launching a best-in-class injectable and oral GLP-1 pipeline in the high-growth global weight-loss market. Read the article here
